• Boehringer Ingelheim is committed to researching and developing innovative treatments in type 2 diabetes. Boehringer Ingelheim research in this area began in 2001 and focuses on new therapeutic compounds with potential for use alone or in combination therapy with other antidiabetes medications. Read more
  • We are a steadfast and dedicated partner to healthcare professionals, patients, governmental and non-governmental organisations in the fight against this condition which affects over 285 million people worldwide. Read more
  • Boehringer Ingelheim is committed to researching and developing new diabetes compounds to improve patients' health and increase overall quality of life. Boehringer Ingelheim carries out drug discovery and development in six therapeutic areas at four major R&D sites and three smaller specialised sites making seven R&D sites in total. Read more
  • Boehringer Ingelheim is committed to researching and developing innovative treatments in type 2 diabetes. Boehringer Ingelheim research in this area began in 2001 and focuses on new therapeutic compounds with potential for use alone or in combination therapy with other antidiabetic medications. Read more